Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer

Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to a subset of patients and there is a critical need to identify robust biomarkers associated with clinical response. In this study, we assessed whether pre-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottonello, Selene, Genova, Carlo, Cossu, Irene, Fontana, Vincenzo, Rijavec, Erika, Rossi, Giovanni, Biello, Federica, Dal Bello, Maria Giovanna, Tagliamento, Marco, Alama, Angela, Coco, Simona, Boccardo, Simona, Vanni, Irene, Ferlazzo, Guido, Moretta, Lorenzo, Grossi, Francesco, Mingari, Maria Cristina, Carrega, Paolo, Pietra, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018763/
https://www.ncbi.nlm.nih.gov/pubmed/32117275
http://dx.doi.org/10.3389/fimmu.2020.00125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018763/
https://www.ncbi.nlm.nih.gov/pubmed/32117275
http://dx.doi.org/10.3389/fimmu.2020.00125

Ejemplares similares